Uwe Platzbecker
Leading expert in myelodysplastic syndromes and immune dysregulation in hematological malignancy.
Top 3 podcasts with Uwe Platzbecker
Ranked by the Snipd community
Sep 7, 2022 • 9min
The need for more effective first-line therapies in MDS
Experts discuss the challenges in developing effective first-line therapies for MDS. They explore IRAC inhibitors, combination approaches, CD47 antibodies, and CAR-T therapy in MDS treatment. The potential of CAR-TI immunotherapy in treating MDS is also discussed.
Jul 22, 2022 • 12min
Immune dysregulation and targeting in MDS
Leading expert Uwe Platzbecker discusses immune dysregulation in myelodysplastic syndromes (MDS) and the development of novel targeting strategies. Topics include IRAC inhibition, NLRP3 and CD47 targeting, innate immune pathways, potential future treatments for MDS and AML, and the importance of identifying biomarkers.
Feb 16, 2021 • 12min
Updates for the management of MDS from ASH 2020
Leading experts in MDS management discuss key updates from ASH 2020. Topics include Phase II IMerge trial results for imetelstat, Phase Ib study on venetoclax and azacitidine combination, and Phase I trial investigating decitabine with ipilimumab for relapsed/refractory MDS or AML.
